Pharmacologic Issues in Management of Chronic Disease

Primary Care - Clinics in Office Practice

Volumn 39, Issue 2, 2012, Pages 345-362

  DeSevo, Gina ^a   Klootwyk, Jacqueline ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adherence; Adverse drug events; Inappropriate prescribing; Polypharmacy

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CARDIOVASCULAR AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OPIATE DERIVATIVE; VITAMIN D; WARFARIN;

ALGORITHM; ARTERY DISEASE; ASK 12; ASK 20; ATHEROSCLEROSIS; BEER CRITERIA; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTERIZED PROVIDER ORDER ENTRY; COST EFFECTIVENESS ANALYSIS; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; ELDERLY CARE; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH BELIEF; HEALTH CARE COST; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK POPULATION; HUMAN; INAPPROPRIATE PRESCRIBING; INTERDISCIPLINARY COMMUNICATION; MEDICATION ALGORITHM; MEDICATION APPROPRIATENESS INDEX; MEDICATION ERROR; MEDICATION NONADHERENCE; MEDICATION THERAPY MANAGEMENT; MORISKY MEDICATION ADHERENCE SCALE; OSTEOPOROSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT GUIDANCE; PHARMACEUTICAL CARE; PHARMACIST; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; SOCIAL STATUS; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; CHRONIC DISEASE; DISEASE MANAGEMENT; DRUG TOXICITY; HUMANS; INAPPROPRIATE PRESCRIBING; MEDICATION ADHERENCE; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PRESCRIPTION DRUGS; RISK FACTORS;

EID: 84861168161     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2012.03.007     Document Type: Review

References (84)

1. Patterns of medication use in the United States 2006: a report from the Slone Survey 2011, Slone Epidemiology Center at Boston University Web site, Available at:, Accessed August 15, 2011. http://www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyWebReport2006.pdf.
2. Qato D.M., Alexander G.C., Conti R.M., et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008, 300(24):2867-2878.
3. Nahin R.L., Pecha M., Welmerink D.B., et al. Concomitant use of prescription drugs and dietary supplements in ambulatory elderly people. J Am Geriatr Soc 2009, 57(7):1197-1205.
4. Murphy SL, Xu J, Kochanek KD. Deaths: preliminary data for 2010. National vital statistics reports, vol. 60(4). Hyattsville (MD): National Center for Health Statistics; 2012. Available at: Accessed January 15, 2012. http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_04.pdf.
5. Hajjar E.R., Cafiero A.C., Hanlon J.T. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007, 5(4):345-351.
6. Frazier S.C. Health outcomes and polypharmacy in elderly individuals. J Gerontol Nurs 2005, 31(9):4-11.
7. Jyrkka J., Enlund H., Korhonen M.J., et al. Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons. Drugs Aging 2009, 26(6):493-503.
8. Rollason V., Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging 2003, 20(11):817-832.
9. Milton J.C., Jackson S.H. Inappropriate polypharmacy: reducing the burden of multiple medication. Clin Med 2007, 7(5):514-517.
10. Fillenbaum G.G., Horner R.D., Hanlon J.T., et al. Factors predicting change in prescription and nonprescription drug use in a community-residing black and white elderly population. J Clin Epidemiol 1996, 49:587-593.
11. Garfinkel D., Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults. Arch Intern Med 2010, 170(18):1648-1654.
12. Fillit H.M., Futterman R., Orland B.I., et al. Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews. Am J Manag Care 1999, 5(5):587-594.
13. Zarowitz B.J., Stebelsky L.A., Muma B.K., et al. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy 2005, 25(11):1636-1645.
14. Liu G.G., Christensen D.B. The continuing challenge of inappropriate prescribing in the elderly: an update of the evidence. J Am Pharm Assoc (Wash) 2002, 42(6):847-857.
15. Gallagher P.F., Barry P.J., Ryan C., et al. Inappropriate prescribing in an acutely ill population of elderly patients as determined by Beers' Criteria. Age Ageing 2008, 37(1):96-101.
16. Gallagher P., O'Mahony D. STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. Age Ageing 2008, 37(6):673-679.
17. Barry P.J., Gallagher P., Ryan C., et al. START (screening tool to alert doctors to the right treatment)-an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing 2007, 36(6):632-638.
18. Budnitz D.S., Shehab N., Kegler S.R., et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007, 147(11):755-765.
19. Spinewine A., Schmader K.E., Barber N., et al. Appropriate prescribing in elderly people: how well can it be measured and optimised?. Lancet 2007, 370(9582):173-184.
20. What is a serious adverse event? 2011, U.S. Food and Drug Administration, Available at:, Accessed August 15, 2011. http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm.
21. Clinical safety data management: definitions and standards for expedited reporting 1995, European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Available at:, Accessed January 13, 2012. http://eudravigilance.ema.europa.eu/human/docs/e2a.pdf.
22. Nixdorff N., Hustey F.M., Brady A.K., et al. Potentially inappropriate medications and adverse drug effects in elders in the ED. Am J Emerg Med 2008, 26(6):697-700.
23. Bates D.W., Spell N., Cullen D.J. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997, 277(4):307-311.
24. Samsa G.P., Hanlon J.T., Schmader K.E. A summated score for the Medication Appropriateness Index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol 1994, 47(8):891-896.
25. Beers M.H., Ouslander J.G., Rollingher I., et al. UCLA Division of Geriatric Medicine. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 1991, 151(9):1825-1832.
26. Beers M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997, 157(14):1531-1536.
27. Fick D.M., Cooper J.W., Wade W.E., et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003, 163(22):2716-2724.
28. Zhan C., Sangl J., Bierman A.S., et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001, 286(22):2823-2829.
29. Chang C.M., Liu P.Y., Yang Y.H., et al. Use of the beers criteria to predict adverse drug reactions among first-visit elderly outpatients. Pharmacotherapy 2005, 25(6):831-838.
30. Passarelli M.C., Jacob-Filho W., Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 2005, 22(9):767-777.
31. Chrischilles E.A., VanGilder R., Wright K., et al. Inappropriate medication use as a risk factor for self-reported adverse drug effects in older adults. J Am Geriatr Soc 2009, 57(6):1000-1006.
32. National Committee for Quality Assurance. NCQA Releases HEDIS 2006; New measures address overuse, follow-up. Available at: Accessed August 15, 2011. http://www.ncqa.org/tabid/277/Default.aspx.
33. National Committee for Quality Assurance. HEDIS, & quality measurement. Available at: Accessed August 15, 2011. http://www.ncqa.org/tabid/59/Default.aspx.
34. Lund B.C., Carnahan R.M., Egge J.A., et al. Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother 2010, 44(6):957-963.
35. Fitzgerald L.S., Hanlon J.T., Shelton P.S., et al. Reliability of a modified medication appropriateness index in ambulatory older persons. Ann Pharmacother 1997, 31(5):543-548.
36. Gallagher P., Ryan C., Byrne S., et al. STOPP (Screening Toll of Older Persons' Prescriptions) and START (screening tool to alert doctors to right treatment): consensus validation. Int J Clin Pharmacol Ther 2008, 46:72-83.
37. Gallagher P.F., O'Connor M.N., O'Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther 2011, 89(6):845-854.
38. Hamilton H., Gallagher P., Ryan C., et al. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med 2011, 171(11):1013-1019.
39. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006, 19(11):1190-1196.
40. Fischer M.A., Stedman M.R., Lii J., et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med 2010, 25(4):284-290.
41. Krousel-Wood M.A., Muntner P., Islam T., et al. Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults. Med Clin North Am 2009, 93(3):753-769.
42. Adherence to long-term therapy: evidence for action 2003, World Health Organization, Available at:, Accessed August 15, 2011. http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf.
43. Ho P.M., Bryson C.L., Rumsfeld J.S. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009, 119(23):3028-3035.
44. Friedman D.S., Okeke C.O., Jampel H.D., et al. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology 2009, 116(6):1097-1105.
45. Yang Y., Thumula V., Pace P.F., et al. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther 2009, 31(10):2178-2188. [discussion: 2150-51].
46. Castaldi P.J., Rogers W.H., Safran D.G., et al. Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease. Chest 2010, 138(3):614-620.
47. Patterson M.E., Blalock S.J., Smith A.J., et al. Associations between prescription copayment levels and β-blocker medication adherence in commercially insured heart failure patients 50 years and older. Clin Ther 2011, 33(5):608-616.
48. Gibson T.B., Mark T.L., McGuigan K.A., et al. The effects of prescription drug copayments on statin adherence. Am J Manag Care 2006, 12(9):509-517.
49. Neugut A.I., Subar M., Wilde E.T., et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 2011, 29(18):2534-2542.
50. Odegard P.S., Gray S.L. Barriers to medication adherence in poorly controlled diabetes mellitus. Educ 2008, 34(4):692-697.
51. Bangalore S., Kamalakkannan G., Parkar S., et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007, 120(8):713-719.
52. Elliott W.J. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich) 2009, 11(7):376-382.
53. Agh T., Inotai A., Meszaros A. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration 2011, 82(4):328-334.
54. Allen LaPointe N.M., Ou F.S., Calvert S.B., et al. Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome. Am Heart J 2011, 161(5):855-863.
55. Schüz B., Marx C., Wurm S., et al. Medication beliefs predict medication adherence in older adults with multiple illnesses. J Psychosom Res 2011, 70(2):179-187.
56. Asche C., LaFleur J., Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011, 33(1):74-109.
57. Bae J.W., Guyer W., Grimm K., et al. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011, 25(3):279-290.
58. DiMatteo M.R., Giordani P.J., Lepper H.S., et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002, 40(9):794-811.
59. Hill M.N., Miller N.H., DeGeest S. American Society of Hypertension Writing Group. ASH position paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich) 2010, 12(10):757-764.
60. Aggarwal B., Mosca L. Lifestyle and psychosocial risk factors predict non-adherence to medication. Ann Behav Med 2010, 40(2):228-233.
61. Cherry S.B., Benner J.S., Hussein M.A., et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health 2009, 12(4):489-497.
62. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24(1):67-74.
63. Lavsa S.M., Holzworth A., Ansani N.T. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc (2003) 2011, 51(1):90-94.
64. Morisky D.E., Ang A., Krousel-Wood M., et al. Predictive validity of a medication adherence measure for hypertension control. J Clin Hypertens 2008, 10(5):348-354.
65. Muntner P., Joyce C., Holt E., et al. Defining the minimal detectable change in scores on the eight-item Morisky Medication Adherence Scale. Ann Pharmacother 2011, 45(5):569-575.
66. Hahn S.R., Park J., Skinner E.P., et al. Development of the ASK-20 adherence barrier survey. Curr Med Res Opin 2008, 24(7):2127-2138.
67. Matza L.S., Yu-Isenberg K.S., Coyne K.S. Further testing of the reliability and validity of the ASK-20 adherence barrier questionnaire in a medical center outpatient population. Curr Med Res Opin 2008, 24(11):3197-3206.
68. Matza L.S., Park J., Coyne K.S., et al. Derivation and validation of the ASK-12 adherence barrier survey. Ann Pharmacother 2009, 43(10):1621-1630.
69. Morello C.M., Chynoweth M., Kim H., et al. Strategies to improve medication adherence reported by diabetes patients and caregivers: results of a taking control of your diabetes survey. Ann Pharmacother 2011, 45:145-153.
70. Carter B.L., Foppe van Mil J.W. Comparative effectiveness research: evaluating pharmacist interventions and strategies to improve medication adherence. Am J Hypertens 2010, 23(9):949-955.
71. Morgado M.P., Morgado S.R., Mendes L.C., et al. Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: review and meta-analysis. Am J Health Syst Pharm 2011, 68(3):241-253.
72. Lee J.K., Grace K.A., Taylor A.J. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006, 296(21):2563-2571.
73. Reports received and reports entered into AERS by year 2011, U.S. Food and Drug Administration, Available at:, Accessed August 15, 2011. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070434.htm.
74. AERS patient outcomes by year 2011, U.S. Food and Drug Administration, Available at:, Accessed August 15, 2011. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070461.htm.
75. Sarkkar U., Lopez A., Maselli J.H., et al. Adverse drug events in U.S. adult ambulatory medical care. Health Serv Res 2011, 46(5):1517-1533.
76. Gurwitz J.H., Field T.S., Harrold L.R., et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003, 289(9):1107-1116.
77. Hanlon J.T., Pieper C.F., Hajjar E.R., et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci 2006, 61(5):511-515.
78. Hajjar E.R., Hanlon J.T., Artz M.B., et al. Adverse drug reaction risk factors in older outpatients. Am J Geriatr Pharmacother 2003, 1(2):82-89.
79. Field T.S., Gurwitz J.H., Harrold L.R., et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 2004, 52(8):1349-1354.
80. Lucado J., Paez K., Elixhauser A. Medication-related adverse outcomes in U.S. hospitals and emergency departments 2008, Agency for Healthcare Research and Quality, Available at:, Accessed August 15, 2011. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb109.pdf.
81. Simonson W., Feinberg J.L. Medication-related problems in the elderly. Drugs Aging 2005, 22(7):559-569.
82. Bressler R., Bahl J.J. Principles of drug therapy for the elderly patient. Mayo Clin Proc 2003, 78(12):1564-1577.
83. Wolfstadt J.I., Gurwitz J.H., Field T.S. The effect of computerized physician order entry with clinical decision support on the rates of adverse drug events: a systematic review. J Gen Intern Med 2008, 23(4):451-458.
84. Medical product safety 2011, Healthpeople.gov, Available at:, Accessed August 15, 2011. http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx%3Ftopicid%3D27.